Tenderwize
Retour à la recherche

Non-exclusive pharmaceutical discount agreement for Denosumab (Prolia) under open-house model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline May 31, 2027 · 276 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Denosumab Prolia (ATC-Code nach WHO: M05BX04)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed volumes; actual demand is unknown and may be low, affecting revenue predictability.

The contracting authority may terminate the open-house procedure early if exclusive agreements are concluded, ending al...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Non-exclusive discount agreement for pharmaceutical products with active substance Denosumab (Prolia)
  • Open-house model allowing continuous participation
Afficher le résumé complet

Non-exclusive pharmaceutical discount agreement under an open-house model for the active substance Denosumab (Prolia) with AOK PLUS. The agreement is open to all pharmaceutical entrepreneurs meeting eligibility criteria, with no guaranteed volumes and no exclusive rights. The contract runs until May 31, 2027, with flexible submission deadlines.

Risques

No guaranteed volumes; actual demand is unknown and may be low, affecting revenue predictability.

The contracting authority may terminate the open-house procedure early if exclusive agreements are concluded, ending al...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs.18 AMG

Eligibility

  • No exclusion grounds under §§123, 124 GWB (self-declaration required)

Administrative

  • Compliance with EU sanctions against Russia (self-declaration required)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; acceptance based on meeting eligibility conditions.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement for Denosumab (Prolia) under open-house model

Non-exclusive discount agreement for Denosumab (Prolia) including biosimilars and imports. Open-house model with no negotiation or exclusivity. Unknown demand; no minimum volumes guaranteed.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Aug 2026 - May 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; acceptance based on meeting eligibility conditions.

Date limite

Deadline May 31, 2027

Détails de la procédure

Date de publication
30 Jun 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
451344-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30